[{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","amount":"$72.2 million","upfrontCash":"Undisclosed","newsHeadline":"Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"CPV-101","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn","highestDevelopmentStatusID":"4","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz\u00ae Regenerative Immunotherapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TwoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel CKD Treatment Candidates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TXR-1208","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cilastatin","moa":"DPEP1","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Telara Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telara Pharma \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"Telara Pha.."},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"NPH-022","moa":"Epoxyeicosatrienoic acid","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Nephraegis Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nephraegis Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Nephraegis.."},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"CCN2","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Tribune Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tribune Therapeutics \/ HEALTHCAPS INDIA LTD","highestDevelopmentStatusID":"4","companyTruncated":"Tribune Th.."},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$561.0 million","upfrontCash":"$12.0 million","newsHeadline":"Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XNW1011","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Sinovent","amount2":0.56000000000000005,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"Capsule","sponsorNew":"Sinovent \/ Everest","highestDevelopmentStatusID":"4","companyTruncated":"Sinovent \/.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX-097","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-C3","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Repirinast","moa":"Mast cell","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TST004","moa":"MASP2","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Repirinast","moa":"Mast cell","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EB003","moa":"STEC bacteria","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bios.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"TLR4","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MZ-301","moa":"APOL1","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosc.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring.."},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$30.0 million","newsHeadline":"Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Teijin Pharma \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pha.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Guangdong Academy of Medical Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Guangdong Academy of Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Repirinast","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United The.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"$91.0 million","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United The.."},{"orgOrder":0,"company":"Miromatrix Medical","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Miromatrix Medical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Miromatrix Medical \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Miromatrix.."}]